{"id":"bebt-209-placebo-capluses","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3649169","moleculeType":"Small molecule","molecularWeight":"417.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEBT-209 Placebo capsules contain no active pharmaceutical ingredient and serve as a control comparator in clinical trials. Placebo formulations are used to establish the baseline effect of the disease, natural history, and investigator/patient bias in phase 3 randomized controlled trials.","oneSentence":"This is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:47.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06998108","phase":"PHASE3","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2022-06-09","conditions":"HR+/HER2- Locally Advanced, Metastatic Breast Cancer","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEBT-209 Placebo capluses","genericName":"BEBT-209 Placebo capluses","companyName":"BeBetter Med Inc","companyId":"bebetter-med-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEBT-209 is a small molecule being studied in combination with Fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer. A clinical trial (NCT06998108) is comparing the efficacy of BEBT-209 in combination with Fulvestrant to a placebo in combination with Fulvestrant in patients who have progressed after prior endocrine therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}